JAC Advance Access originally published online on November 18, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2002) 50, 779-792
© 2002 The British Society for Antimicrobial Chemotherapy
Reviews |
Cyclin-dependent kinases as cellular targets for antiviral drugs
Departments of Biochemistry and Medical Microbiology and Immunology, Signal Transduction Research Group, University of Alberta, 315C Heritage Medical Research Center, Edmonton, Alberta T6G 2S2, Canada
Cyclin-dependent kinases (cdks) are required for replication of viruses that replicate only in dividing cells, such as adeno- and papillomaviruses. Recently, cdks have been shown to be required also for replication of viruses that can replicate in non-dividing cells, such as HIV-1 and herpes simplex virus types 1 and 2 (HSV-1 and -2). In these experiments, pharmacological cdk inhibitors (PCIs) were shown to have potent antiviral activity in vitro against HIV-1, HSV-1 and -2, human cytomegalovirus, varicella–zoster virus, and to inhibit specific functions of other viruses. Since two PCIs, flavopiridol and roscovitine, are proving to be non-toxic in human clinical trials against cancer, PCIs may be useful as antivirals. As significant advantages, PCIs are active in vitro against many viruses, including drug-resistant strains of HIV-1 and HSV-1, and mutant strains of HIV-1 or HSV-1 resistant to PCIs have not been identified in spite of intense efforts. Furthermore, the antiviral effects of a PCI and a conventional antiviral drug are additive. The aetiopathogenesis of several diseases, such as Kaposi’s sarcoma, HPV-induced cervical carcinoma and HIV-associated nephropathy (HIVAN), among others, includes replication or expression of proteins by viruses that require cdks. Thus, PCIs could target both the aetiological agent (the virus) and the pathogenic mechanisms (cell replication). Two important questions regarding the antiviral activities of PCIs are the focus of current research efforts, (i) the identity of the specific cdks that mediate the antiviral activities of PCIs, and (ii) whether PCIs have antiviral activity in vivo at non-toxic doses.
* Tel: +1-780-492-6265; Fax: +1-780-492-3383; E-mail: luis.schang{at}ualberta.ca
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Teale, S. Campbell, N. Van Buuren, W. C. Magee, K. Watmough, B. Couturier, R. Shipclark, and M. Barry Orthopoxviruses Require a Functional Ubiquitin-Proteasome System for Productive Replication J. Virol., March 1, 2009; 83(5): 2099 - 2108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Agbottah, C. de La Fuente, S. Nekhai, A. Barnett, A. Gianella-Borradori, A. Pumfery, and F. Kashanchi Antiviral Activity of CYC202 in HIV-1-infected Cells J. Biol. Chem., January 28, 2005; 280(4): 3029 - 3042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Diwan, J. J. Lacasse, and L. M. Schang Roscovitine Inhibits Activation of Promoters in Herpes Simplex Virus Type 1 Genomes Independently of Promoter-Specific Factors J. Virol., September 1, 2004; 78(17): 9352 - 9365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-H. Li, P.-Z. Tao, Y.-Z. Liu, and J.-D. Jiang Geldanamycin, a Ligand of Heat Shock Protein 90, Inhibits the Replication of Herpes Simplex Virus Type 1 In Vitro Antimicrob. Agents Chemother., March 1, 2004; 48(3): 867 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kudoh, T. Daikoku, Y. Sugaya, H. Isomura, M. Fujita, T. Kiyono, Y. Nishiyama, and T. Tsurumi Inhibition of S-Phase Cyclin-Dependent Kinase Activity Blocks Expression of Epstein-Barr Virus Immediate-Early and Early Genes, Preventing Viral Lytic Replication J. Virol., January 1, 2004; 78(1): 104 - 115. [Abstract] [Full Text] [PDF]
|
|